GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Ocuphire Pharma Inc.
OncoCyte is a company specializing in the development and commercialization of diagnostic tests for cancer detection. Its stock price reflects its efforts to introduce its tests into clinical practice, a long and complex process.
Share prices of companies in the market segment - Pharma eyes
Ocuphire Pharma is a biopharmaceutical company focused on developing treatments for diseases of the anterior and posterior segments of the eye. We've categorized it as "Pharma: Eye." The chart below shows how investors value companies operating in the niche ophthalmology sector.
Broad Market Index - GURU.Markets
Ocuphire Pharma is a biopharmaceutical company focused on developing treatments for diseases of the anterior and posterior segments of the eye. We've categorized it as "Pharma: Eye." The chart below shows how investors value companies operating in the niche ophthalmology sector.
Change in the price of a company, segment, and market as a whole per day
OCUP - Daily change in the company's share price Ocuphire Pharma Inc.
For Ocuphire Pharma, Inc., a company developing drugs for eye diseases, daily volatility reflects sensitivity to FDA decisions. This metric is key to assessing the risks of its late-stage drugs.
Daily change in the price of a set of shares in a market segment - Pharma eyes
Ocuphire Pharma is a biopharmaceutical company specializing in the treatment of eye diseases. Ophthalmology is a highly specialized and competitive field. The chart below shows volatility in this sector, allowing you to assess how OCUP shares react to industry news.
Daily change in the price of a broad market stock, index - GURU.Markets
Ocuphire Pharma is a biotech company specializing in the treatment of eye diseases. Its stock price depends on clinical trial success and regulatory approval. These events create unique price movements that contribute to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Ocuphire Pharma Inc.
Ocuphire Pharma's year-over-year performance is a story about the development of its ophthalmology drugs. Its market capitalization over the next 12 months is entirely dependent on FDA decisions. Successful approval of its eye drops for pupil dilation and presbyopia treatment could be a fundamental breakthrough for the company and provide it with a stable revenue stream.
Annual dynamics of market capitalization of the market segment - Pharma eyes
Ocuphire, a late-stage biotech company, develops drugs for the treatment of eye diseases. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ocuphire Pharma, an ophthalmology company developing drugs for eye diseases, operates in a market driven by an aging population. Its year-over-year market capitalization dynamics are based on expectations for clinical trial results and FDA approvals.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Ocuphire Pharma Inc.
Ocuphire is a late-stage ophthalmology company. Its monthly performance is entirely dependent on the results of its key clinical trials and its interactions with the FDA. Regulatory news regarding its drugs is a key event for investors.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
Ocuphire Pharma is a biopharmaceutical company specializing in the development of drugs for the treatment of eye diseases, both anterior and posterior. The chart below shows the overall dynamics of the ophthalmic pharmaceutical sector, driven by an aging population and the need for new treatments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often live in a world of their own, where clinical trial news trumps overall market trends. The chart below shows the pulse of the broader market. Does Ocuphire Pharma, Inc. move in sync with the broader market, or do its R&D developments create a completely separate story?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Ocuphire Pharma Inc.
The weekly performance of Ocuphire Pharma, an ophthalmology company, reflects the search for new treatments for eye diseases. Share prices are reacting sharply to clinical trial data and FDA decisions that could approve its drugs for a wide range of patients.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
Ocuphire Pharma develops drugs for the treatment of eye diseases. Ophthalmology is a large and competitive market. The chart shows how the company's stock performance compares to the sector, allowing one to assess how its developments stand out from other players and how the market perceives their potential.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Ocuphire Pharma is a biopharmaceutical company focused on eye diseases. Its success depends on the results of clinical trials. The chart will help you understand: does Ocuphire live in its own world of scientific news, or are the overall market conditions and risk appetite actually influencing its stock price?
Market capitalization of the company, segment and market as a whole
OCUP - Market capitalization of the company Ocuphire Pharma Inc.
Ocuphire's market capitalization tells the story of a biotech company focused on treating eye diseases. Its volatile chart is a trajectory of clinical trials and FDA decisions. Its dynamics reflect hopes for approval of its pupil dilation and presbyopia treatments, which could open up large commercial markets.
OCUP - Share of the company's market capitalization Ocuphire Pharma Inc. within the market segment - Pharma eyes
Ocuphire Pharma specializes in drugs for the treatment of eye diseases. The company's share of the ophthalmology segment's market capitalization is directly dependent on the success of its clinical programs. The chart below shows how research news affects its share price and investor expectations.
Market capitalization of the market segment - Pharma eyes
Ocuphire Pharma is a biopharmaceutical company focused on eye diseases. The chart below shows the overall market capitalization of this sector. Its dynamics reflect the constant need for new treatments, where Ocuphire is trying to find its niche with its niche drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Ocuphire Pharma is a biotech company focused on eye diseases. Its market cap reflects the potential of its drugs to offer new solutions for treating and improving vision. Its performance on the overall chart reflects the progress and setbacks in ophthalmological science.
Book value capitalization of the company, segment and market as a whole
OCUP - Book value capitalization of the company Ocuphire Pharma Inc.
Ocuphire Pharma's book value is its capital invested in the development and commercialization of drugs for the treatment of various eye diseases. This is a real, scientific foundation focused on ophthalmology. How has this specialized biotech asset changed during clinical trials? The chart below shows its dynamics.
OCUP - Share of the company's book capitalization Ocuphire Pharma Inc. within the market segment - Pharma eyes
Ocuphire Pharma develops drugs for the treatment of eye diseases, which requires research laboratories. The chart shows the share of these research-intensive tangible assets, reflecting the physical foundation of its ophthalmic innovations.
Market segment balance sheet capitalization - Pharma eyes
Ocuphire, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
Ocuphire Pharma's capital isn't its factories, but rather its portfolio of patents and clinical trial data for eye treatments. The company's assets are the capitalized results of its R&D activities. The chart below shows how this ophthalmology-focused biotech compares in terms of asset size.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Ocuphire Pharma Inc.
Ocuphire Pharma develops drugs for eye diseases. Its balance sheet is based on clinical research expenses. Its market capitalization is a bet on successful completion of trials and drug approval. The MvsBCap_Co chart for this company represents the path from a scientific hypothesis to a potential commercial product in the eyes of investors.
Market to book capitalization ratio in a market segment - Pharma eyes
Ocuphire Pharma is a biopharmaceutical company specializing in the development of drugs for the treatment of eye diseases. Its market valuation on the chart is heavily dependent on the results of clinical trials and the commercialization potential of its lead drug candidates.
Market to book capitalization ratio for the market as a whole
Ocuphire Pharma, Inc. specializes in eye treatments. The company's value is derived from its intellectual property and potential future sales. This chart allows investors to see how expectations for niche biotech companies differ from the overall market sentiment.
Debts of the company, segment and market as a whole
OCUP - Company debts Ocuphire Pharma Inc.
Ocuphire Pharma, a late-stage ophthalmology company, is using capital to complete clinical trials and prepare for the commercial launch of its drugs. This chart shows how the company is funding its decisive push to market, aiming to offer new treatments for common eye diseases.
Market segment debts - Pharma eyes
Ocuphire Pharma is a late-stage biotech company focused on eye diseases. Moving closer to commercialization may require raising capital to build a sales force. This chart shows how the company is funding its final clinical trials and preparing for a potential product launch.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Ocuphire Pharma Inc.
Ocuphire Pharma is a biopharmaceutical company specializing in eye treatments. Developing and commercializing ophthalmological drugs is a lengthy and expensive process. This chart shows the company's reliance on debt to fund its clinical trials, which is a measure of its financial risk.
Market segment debt to market segment book capitalization - Pharma eyes
Ocuphire Pharma is a biopharmaceutical company focused on developing drugs for the treatment of eye diseases. Ophthalmology is a large and stable market. The chart shows the overall debt burden in the pharmaceutical industry, providing context for assessing how Ocuphire finances its clinical trials.
Debt to book value of all companies in the market
Ocuphire Pharma, Inc., which focuses on treating eye diseases, is in the clinical stage, requiring significant and risky investments in R&D. This chart, reflecting the overall market debt load, provides context. It helps understand how the company's financial strategy is typical for the biotech sector, where revenues can take years to materialize.
P/E of the company, segment and market as a whole
P/E - Ocuphire Pharma Inc.
Ocuphire Pharma is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of eye diseases. This chart shows the market valuation of its pipeline. This valuation depends on the clinical trial results and commercial potential of its ophthalmology drug candidates.
P/E of the market segment - Pharma eyes
This industry chart for biopharmaceutical companies serves as a benchmark for Ocuphire Pharma. It reflects the overall sentiment in the sector. Comparisons with it help understand how the market views Ocuphire's pipeline of late-stage ophthalmic treatments and whether it believes they have commercial potential if approved.
P/E of the market as a whole
Ocuphire Pharma is a biopharmaceutical company specializing in the treatment of eye diseases. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Ocuphire Pharma Inc.
This chart from Ocuphire Pharma, Inc., a company focused on treating eye diseases, shows market expectations for its drug candidates. It reflects investor confidence in the commercial potential of its developments for treating conditions such as presbyopia and diabetic retinopathy.
%20P%2FE%20Ocuphire%20Pharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Ocuphire-Pharma-Inc.&v=1772350885788 "Chart of the company's future (projected) P/E Ocuphire Pharma Inc.")
Future (projected) P/E of the market segment - Pharma eyes
Ocuphire Pharma is a clinical-stage biopharmaceutical company specializing in the development of drugs for the treatment of both anterior and posterior segment ophthalmology. This chart shows industry forecasts, helping to assess how the market perceives the potential of Ocuphire's portfolio in the large and competitive field of ophthalmology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772350885792 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
Ocuphire Pharma, Inc. develops drugs for the treatment of eye diseases. This is a specialized area with high potential. The company's valuation depends on the results of clinical trials. This overall market sentiment affects the ability of niche biotech companies to raise capital to complete their development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772350885796 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Ocuphire Pharma Inc.
Ocuphire Pharma is a biopharmaceutical company focused on developing treatments for eye diseases. While in late-stage clinical trials, it is losing money but is approaching potential commercialization. This chart shows the company's financial trajectory as it prepares for potential market launch.
Profit of companies in the market segment - Pharma eyes
Ocuphire Pharma develops medications for the treatment of both anterior and posterior segment eye diseases. This chart, which shows profitability in the ophthalmology sector, demonstrates the significant demand for vision treatments. Their medications target conditions such as presbyopia and diabetic retinopathy, which affect millions of people.
Overall market profit
Ocuphire Pharma develops drugs for the treatment of both anterior and posterior segment eye diseases. This is a specialized area with significant unmet needs. The company's success depends on clinical trial results and regulatory approval. Overall economic stability, reflected in this chart, is important for funding ophthalmology research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Ocuphire Pharma Inc.
Ocuphire Pharma develops medications for the treatment of both anterior and posterior segment eye diseases. Its pipeline includes candidates for the treatment of presbyopia and night blindness. This chart aggregates analyst opinions on the likelihood of approval for these medications, which is key to assessing the ophthalmology company's future.
%20profit%20of%20the%20company%20Ocuphire%20Pharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Ocuphire-Pharma-Inc.&v=1772350885808 "Graph of future (projected) profit of the company Ocuphire Pharma Inc.")
Future (predicted) profit of companies in the market segment - Pharma eyes
Ocuphire Pharma is a late-stage biopharmaceutical company developing drugs for the treatment of eye diseases. Its pipeline includes candidates for the treatment of presbyopia and other conditions. The company's future depends on regulatory approval. This chart for the pharmaceutical sector shows general expectations for innovation in ophthalmology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772350885812 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
Ocuphire Pharma develops drugs for the treatment of eye diseases. The company's success depends on the results of clinical trials. However, the overall economic situation reflected in this forecast affects the investment climate in the biotech sector and the valuation of companies in development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772350885815 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Ocuphire Pharma Inc.
Ocuphire Pharma is a biopharmaceutical company developing drugs to treat eye diseases. For a late-stage clinical company, this chart is key. It shows how investors assess the potential future sales of its candidates, betting on their approval and commercial success in the large ophthalmology niche.
P/S market segment - Pharma eyes
Ocuphire Pharma develops drugs for the treatment of both anterior and posterior segment eye diseases. The clinical-stage company's valuation depends on the success of its developments. This chart, which reflects the average biotech valuation, helps investors understand how expectations for Ocuphire's ophthalmology portfolio compare to overall sector trends.
P/S of the market as a whole
Ocuphire Pharma is a biopharmaceutical company focused on developing treatments for both anterior and posterior segment eye diseases. This chart, which reflects market revenue estimates, serves as a benchmark for Ocuphire's expectations. It demonstrates the value investors place on the company's development pipeline in one of the most in-demand areas of medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Ocuphire Pharma Inc.
Ocuphire Pharma is a clinical-stage biopharmaceutical company focused on developing treatments for eye diseases. Its candidates target large markets. This chart reflects investor expectations regarding the success of clinical trials and the future commercial potential of its eye drops.
%20P%2FS%20Ocuphire%20Pharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Ocuphire-Pharma-Inc.&v=1772350885827 "The graph of the company's future (projected) P/S Ocuphire Pharma Inc.")
Future (projected) P/S of the market segment - Pharma eyes
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for anterior and posterior segment eye diseases. This chart reflects average future revenue expectations in the ophthalmology sector. It provides an insight into the market's perception of the vision-improving potential of Ocuphire's products.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772350885830 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
Ocuphire Pharma is a biopharmaceutical company focused on developing drugs for the treatment of eye diseases. This indicator reflects collective market expectations. The company's success in developing new eye drops, for example, for the treatment of presbyopia or dilated pupils, could open the door to a huge consumer market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772350885834 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Ocuphire Pharma Inc.
This chart shows the revenue of Ocuphire Pharma, a company specializing in eye medications. Following the recent approval of its eye drops, revenue has begun to accrue from commercial sales. The trend will show how successfully the drug is gaining market acceptance and acceptance by ophthalmologists.
Sales of companies in the market segment - Pharma eyes
Ocuphire Pharma develops medications to treat eye diseases of both the anterior and posterior segments. This chart illustrates the growth of the ophthalmology market. The company's drugs target common conditions such as presbyopia and night blindness, and if successful, could capture a significant share of this multi-billion-dollar and growing sector.
Overall market sales
Ocuphire Pharma is a biopharmaceutical company specializing in the treatment of eye diseases. Its market capitalization depends on the results of clinical trials and the commercial potential of its drugs. The overall economic situation, reflected in this chart, influences the investment climate in the biotech sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Ocuphire Pharma Inc.
Ocuphire Pharma is a biopharmaceutical company specializing in the development of drugs for the treatment of eye diseases. Future revenues are dependent on the approval and commercial launch of its drug candidates. The chart reflects analyst expectations for the potential of its ophthalmological developments.
%20sales%20of%20the%20company%20Ocuphire%20Pharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Ocuphire-Pharma-Inc.&v=1772350885850 "Schedule of future (projected) sales of the company Ocuphire Pharma Inc.")
Future (projected) sales of companies in the market segment - Pharma eyes
Ocuphire Pharma is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of ocular diseases, both anterior and posterior. This chart shows the forecast for the entire ophthalmology market, a large and steadily growing segment of the pharmaceutical industry, where Ocuphire is seeking its niche.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772350885856 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
Ocuphire Pharma is a late-stage biopharmaceutical company developing drugs for the treatment of eye diseases. Its valuation is dependent on successful clinical trials and regulatory approval. This chart, reflecting overall market sentiment, influences investor valuations of the company ahead of key commercial and regulatory events.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772350885859 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Ocuphire Pharma Inc.
Ocuphire Pharma develops drugs for the treatment of eye diseases. In late-stage clinical trials, the company is approaching potential commercialization. This chart shows its net losses—investments in the final stages of development required to bring a new ophthalmology product to a multi-billion dollar market.
Market segment marginality - Pharma eyes
Ocuphire Pharma is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of eye diseases. With an approved product, the company's profitability depends on its successful sales and progress in developing other candidates. This chart shows the commercial results of their efforts in the highly specialized field of ophthalmology.
Market marginality as a whole
Ocuphire Pharma is a biopharmaceutical company focused on developing drugs for the treatment of ocular diseases, both anterior and posterior. Their candidates target multiple indications. This overall profitability curve is irrelevant to them. Their value and future depend solely on the results of clinical trials in ophthalmology.
Employees in the company, segment and market as a whole
Number of employees in the company Ocuphire Pharma Inc.
Ocuphire Pharma is a biopharmaceutical company specializing in the treatment of eye diseases. It operates with a small but experienced team focused on clinical trials. This schedule reflects its lean and efficient model, typical of late-stage biotechs.
Share of the company's employees Ocuphire Pharma Inc. within the market segment - Pharma eyes
Ocuphire Pharma is a biopharmaceutical company specializing in the development of drugs for the treatment of eye diseases. This chart reflects its share of the total number of researchers in this specialized field. It is an indicator of the scale of its clinical programs and the size of its scientific team working on new treatments for eye diseases.
Number of employees in the market segment - Pharma eyes
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for eye diseases. This chart shows employment trends in the ophthalmology sector. The growth in the number of clinicians and regulatory affairs specialists is directly related to progress in trials and the company's progress toward bringing its drugs to market.
Number of employees in the market as a whole
Ocuphire Pharma develops drugs for the treatment of eye diseases. The company's success depends on the results of clinical trials and the subsequent launch of its products. A stable economic environment, reflected in this chart, is important for securing R&D funding and for the solvency of the healthcare system, which will cover the costs of new drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Ocuphire Pharma Inc. (OCUP)
Ocuphire Pharma specializes in drugs for the treatment of eye diseases (presbyopia, night blindness). It is a highly specialized biotech company. Like its peers in the sector, the company has a small staff at the clinical stage, and its market capitalization is based on expectations. The chart shows the market's value of the team's intellectual capital and the potential market size for their future eye drops. The value of patents is more important here than the number of employees.
%20of%20the%20company%20Ocuphire%20Pharma%20Inc.%20(OCUP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Ocuphire-Pharma-Inc.-OCUP&v=1772350885885 "Chart of market capitalization per employee (in thousands of dollars) of the company Ocuphire Pharma Inc. (OCUP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
Ocuphire Pharma is a biopharmaceutical company specializing in the development of drugs for the treatment of eye diseases. Its value is determined by the potential of its clinical programs. This chart shows the high market valuation of its scientific assets and prospects in the highly specialized field of ophthalmology, based on its small team of scientists.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772350885888 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
Ocuphire Pharma is a clinical-stage biopharmaceutical company focused on treating eye diseases. The chart shows their ophthalmology valuation. It reflects how the market views the potential of their drugs for treating common conditions like presbyopia, where even modest success can lead to significant sales.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772350885891 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Ocuphire Pharma Inc. (OCUP)
Ocuphire Pharma is a clinical-stage biotech company specializing in the development of drugs for eye diseases (e.g., eye drops for dilation and constriction). This is R&D. This chart shows the company's capital burn: the amount of capital spent on each scientist during expensive clinical trials.
%20Chart%20Ocuphire%20Pharma%20Inc.%20(OCUP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Ocuphire-Pharma-Inc.-OCUP&v=1772350885895 "Company Profit Per Employee (in thousands of dollars) Chart Ocuphire Pharma Inc. (OCUP)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
Ocuphire Pharma is a late-stage biopharmaceutical company specializing in eye treatments. The company is on the cusp of commercialization, reflecting the transition from R&D spending to generating initial sales revenue through its new marketing department.
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772350885897 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
Ocuphire Pharma is a clinical-stage biotech company specializing in the treatment of eye diseases. It's an R&D company and has no profit. This chart shows the company's capital burn rate: the operating loss calculated per team of scientists developing a new drug through expensive clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772350885899 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Ocuphire Pharma Inc. (OCUP)
Ocuphire Pharma is a biopharmaceutical company focused on developing treatments for eye diseases. This chart reflects the progress of its research commercialization. Revenue growth at this stage is likely driven by milestone payments from partners following successful clinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Ocuphire-Pharma-Inc.-OCUP&v=1772350885901 "Sales chart per company employee Ocuphire Pharma Inc. (OCUP)")
Sales per employee in the market segment - Pharma eyes
Ocuphire Pharma is a biotech company focused on treating eye diseases. Their drugs target conditions such as night blindness and pupil reversal. This chart shows how productive their team is. It measures revenue (from partnerships or early sales) per employee, reflecting their commercial progress in ophthalmology.
Sales per employee for the market as a whole
Ocuphire Pharma (OCUP) is a biotech company specializing in eye treatments. The company is in the late stage of preparing to commercialize its eye drops. This chart illustrates its pre-launch readiness: a large team of specialists is focused on R&D and launch preparations, which is an investment in future revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Ocuphire Pharma Inc. (OCUP)
Ocuphire Pharma is a biotech company specializing in eye treatments. It has an approved drug, Ryzumvi. The bearish sentiment shown in this chart likely reflects bets on a very slow commercial launch of this drug or the failure of its other candidates in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Ocuphire-Pharma-Inc.-OCUP&v=1772350885910 "Short Shares Chart for the Company Ocuphire Pharma Inc. (OCUP)")
Shares shorted by market segment - Pharma eyes
Ocuphire Pharma is a biopharmaceutical company focused on developing treatments for eye diseases. Their focus is on highly specialized ophthalmology. This chart shows the overall investor sentiment for the entire ophthalmology biotech sector. It reflects the extent to which the market as a whole believes in breakthroughs in this field or, conversely, anticipates setbacks in the industry.
Shares shorted by the overall market
Ocuphire (OCUP) is a clinical-stage biotech. Its value reflects the hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse that require refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Ocuphire Pharma Inc. (OCUP)
This oscillator for Ocuphire is a binary bet on ophthalmology. The company received FDA approval for pupil dilating drops (for reversal). "Overheating" (above 70) occurs due to positive data on other drugs (night blindness). A clinical failure or a slow start to sales of the approved drug leads to "oversold" conditions.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Ocuphire-Pharma-Inc.-OCUP&v=1772350885920 "RSI 14 indicator chart for the company's stock Ocuphire Pharma Inc. (OCUP)")
RSI 14 Market Segment - Pharma eyes
Ocuphire (OCUP) is a pharmaceutical company focused on the eyes. They are developing eye drops to treat presbyopia (age-related farsightedness) and improve night vision. This chart tracks the overall sentiment in the Pharma/Ophthalmology sector. It helps investors understand whether the entire biotech segment is overhyped or oversold due to a lack of success.
RSI 14 for the overall market
For Ocuphire Pharma, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OCUP (Ocuphire Pharma Inc.)
Ocuphire Pharma (OCUP) is a biopharmaceutical company focused on treating eye diseases. Its lead candidate (Nyxol) is designed to reverse pupil dilation. This chart shows the average target price. It reflects analysts' confidence in the drug's FDA approval and its commercial potential in the optometry market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OCUP-Ocuphire-Pharma-Inc.&v=1772350885930 "A chart showing analyst consensus forecasts for the expected stock price. OCUP (Ocuphire Pharma Inc.)")
The difference between the consensus estimate and the actual stock price OCUP (Ocuphire Pharma Inc.)
Ocuphire (OCUP) is a sharpshooter in ophthalmology. Their R&D portfolio targets niche but important eye conditions (night blindness, dilated pupils). This chart measures the gap between the current price and the consensus target price. It shows the potential analysts see in their ability to bring these drugs to market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OCUP-Ocuphire-Pharma-Inc.&v=1772350885933 "A chart showing the difference between the consensus forecast and the actual stock price. OCUP (Ocuphire Pharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
Ocuphire is an ophthalmic biotech whose R&D focuses on the anterior portion of the eye (presbyopia drops, night blindness). This chart displays analysts' overall expectations for the entire ophthalmic pharmaceutical sector. It shows whether experts believe the new vision-improving drops will be commercially successful.
Analysts' consensus forecast for the overall market share price
Ocuphire Pharma (OCUP) is a biopharmaceutical company focused on the anterior portion of the eye. They are developing niche eye drops for the treatment of presbyopia (age-related farsightedness) and night blindness. This chart shows the overall risk appetite, reflecting the market's willingness to fund R&D companies solving niche medical problems.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Ocuphire Pharma Inc.
Ocuphire is a biotech eye disease hunter. Their signature feature is an R&D pipeline of small molecules for the treatment of the anterior (dry eye) and posterior (diabetic retinopathy) parts of the eye. This graph is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data and their (difficult) dialogue with the FDA.
AKIMA Market Segment Index - Pharma eyes
Ocuphire Pharma (OCUP) is a highly specialized ophthalmic pharmaceutical company. They don't treat glaucoma, but rather address niche issues such as pupil dilation reversal and night vision improvement. This chart compares their composite index to the sector, showing how their niche ophthalmology R&D strategy outperforms their competitors.
The AKIM Index for the overall market
Ocuphire Pharma is a biopharmaceutical company developing eye drops for the treatment of eye diseases (presbyopia, night vision impairment). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this late-stage ophthalmology company stacks up against the backdrop of overall economic trends.
